DAX ®13.352,38+0,52%TecDAX ®3.065,42+0,53%S&P FUTURE3.183,70+0,27%Nasdaq 100 Future8.521,00+0,35%
finanztreff.de

PRESS RELEASE: Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: MorphoSys AG / Key word(s): Study results
Results for Bimagrumab in Obesity and Type 2 Diabetes presented by
MorphoSys's Partner (news with additional features)

2019-11-11 / 22:02
The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, November 11, 2019

*Results for Bimagrumab in Obesity and Type 2 Diabetes *
*presented by MorphoSys's Partner*

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR)
announced today that its licensee Novartis presented phase 2 results for
bimagrumab, a human anti-activin receptor monoclonal antibody developed by
Novartis and generated utilizing MorphoSys's proprietary HuCAL antibody
technology. The data from the trial in overweight and obese adults with type
2 diabetes (T2D) were presented on November 7 as a late breaking poster at
the Obesity Week 2019 in Las Vegas, USA.

According to the abstract, the double-blinded, placebo-controlled study
showed that
bimagrumab treatment over 48 weeks was safe and well tolerated. The
treatment reduced body fat and weight while increasing lean body mass (LBM).
At week 48, fat mass decreased 21% (7.5 kg) in bimagrumab- vs. 0.5% (0.2 kg)
in placebo-treated subjects (p<0.001) and HbA1c decreased 0.76% points in
the bimagrumab group vs. an increase of 0.04% points in the placebo group
(p=0.005). Weight decreased 6.5% (5.9 kg) in bimagrumab- vs. 0.8% (0.8 kg)
in placebo-treated subjects (p<0.001); LBM increased 3.6 % (1.7 kg) in the
bimagrumab group vs. a decrease of 0.8% (0.4 kg) in the placebo group
(p<0.001); and BMI was reduced 6.7% (2.2 kg/m2) in the bimagrumab group vs.
0.8% (0.3 kg/m2) in the placebo group (p<0.001).

Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys AG, said: "We
are very pleased to see these data from this clinical study in type 2
diabetes. We look forward to the further development of bimagrumab as a
potential treatment option in this indication."

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
exceptional, innovative therapies for patients suffering from serious
diseases. The focus is on cancer. Based on its leading expertise in
antibody, protein and peptide technologies, MorphoSys, together with its
partners, has developed and contributed to the development of more than 100
product candidates, of which 28 are currently in clinical development. In
2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis,
became the first drug based on MorphoSys's antibody technology to receive
regulatory approval. The Company's most advanced proprietary product
candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough
therapy designation for the treatment of patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany,
the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US
Inc., has approximately 405 employees. More information at
https://www.morphosys.com [1].

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio
Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys
Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, including the expectations regarding the
clinical development of bimagrumab in obesity and type 2 diabetes and the
further clinical development of bimagrumab by Novartis. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the
date of this release and involve known and unknown risks and uncertainties,
which might cause the actual results, financial condition and liquidity,
performance or achievements of MorphoSys, or industry results, to be
materially different from any historic or future results, financial
conditions and liquidity, performance or achievements expressed or implied
by such forward-looking statements. In addition, even if MorphoSys' results,
performance, financial condition and liquidity, and the development of the
industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are MorphoSys'
expectations regarding the clinical development of bimagrumab in obesity and
type 2 diabetes and the further clinical development of bimagrumab by
Novartis, MorphoSys' reliance on collaborations with third parties,
estimating the commercial potential of its development programs and other
risks indicated in the risk factors included in MorphoSys's Annual Report on
Form 20-F and other filings with the US Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
MorphoSys expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.

*For more information, please contact:*

*MorphoSys A**G*

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
Sarah.Fakih@morphosys.com
Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
Julia.Neugebauer@morphosys.com
Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
Verena.Kupas@morphosys.com

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=XEWQQBQUFM [2]
Document title: Media Release

2019-11-11 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 909973

End of News DGAP News Service

909973 2019-11-11


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3e1886fbba4d35045db9993a27da4719&application_id=909973&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=780605ad77a9c6612c1b5b9a03c7fb9d&application_id=909973&site_id=vwd&application_name=news


(END) Dow Jones Newswires

November 11, 2019 16:02 ET ( 21:02 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 51 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen